Trump's Bold Tariff Plan Ignites Urgent Search for Domestic Drug Manufacturers

In a significant twist to the ongoing discourse surrounding U.S. pharmaceuticals, former President Donald Trump's recent tariff initiative has propelled a serious conversation about the necessity of domestic drug manufacturing. As his administration reignites the debate, government officials and industry leaders are scrambling to identify U.S. manufacturers that can fulfil the growing demand for homegrown pharmaceuticals amidst soaring prices and increasing reliance on foreign production.

Continue reading